- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Shaheen Tomah, MD
- 전화번호: 240-235-0145
- 이메일: performa@altimmune.com
연구 장소
-
-
Alabama
-
Dothan, Alabama, 미국, 36301
- 모병
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, 미국, 85224
- 모병
- Altimmune Clinical Study Site
-
Tucson, Arizona, 미국, 85712
- 모병
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, 미국, 72205
- 모병
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, 미국, 72117
- 모병
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, 미국, 92708
- 모병
- Altimmune Clinical Study Site
-
Fresno, California, 미국, 93720
- 모병
- Altimmune Clinical Study Site
-
Gardena, California, 미국, 90247
- 모병
- Altimmune Clinical Study Site
-
Huntington Park, California, 미국, 90255
- 모병
- Altimmune Clinical Study Site
-
La Mesa, California, 미국, 91942
- 모병
- Altimmune Clinical Study Site
-
Long Beach, California, 미국, 90815
- 모병
- Altimmune Clinical Study Site
-
Orange, California, 미국, 92866
- 모병
- Altimmune Clinical Study Site
-
Orange, California, 미국, 92868
- 모병
- Altimmune Clinical Study Site
-
Poway, California, 미국, 92064
- 모병
- Altimmune Clinical Study Site
-
Van Nuys, California, 미국, 91405
- 모병
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, 미국, 80113
- 모병
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, 미국, 33434
- 모병
- Altimmune Clinical Study Site
-
Bradenton, Florida, 미국, 34209
- 모병
- Altimmune Clinical Study Site
-
Miami, Florida, 미국, 33173
- 모병
- Altimmune Clinical Study Site
-
Miami, Florida, 미국, 33122
- 모병
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, 미국, 33016
- 모병
- Altimmune Clinical Study Site
-
Ocala, Florida, 미국, 34471
- 모병
- Altimmune Clinical Study Site
-
Orlando, Florida, 미국, 32803
- 모병
- Altimmune Clinical Study Site
-
Port Orange, Florida, 미국, 32127
- 모병
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, 미국, 30720
- 모병
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, 미국, 46635
- 모병
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, 미국, 71220
- 모병
- Altimmune Clinical Study Site
-
Marrero, Louisiana, 미국, 70072
- 모병
- Altimmune Clinical Study Site
-
Monroe, Louisiana, 미국, 71201
- 모병
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, 미국, 20708
- 모병
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, 미국, 02740
- 모병
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, 미국, 65201
- 모병
- Altimmune Clinical Study Site
-
Kansas City, Missouri, 미국, 64131
- 모병
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, 미국, 87107
- 모병
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, 미국, 28304
- 모병
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, 미국, 44144
- 모병
- Altimmune Clinical Study Site
-
Springboro, Ohio, 미국, 45066
- 모병
- Altimmune Clinical Study Site
-
Westlake, Ohio, 미국, 44145
- 모병
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, 미국, 02818
- 모병
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, 미국, 78757
- 모병
- Altimmune Clinical Study Site
-
Bellaire, Texas, 미국, 77401
- 모병
- Altimmune Clinical Study Site
-
Brownsville, Texas, 미국, 78520
- 모병
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, 미국, 78404
- 모병
- Altimmune Clinical Study Site
-
Dallas, Texas, 미국, 75230
- 모병
- Altimmune Clinical Study Site
-
Edinburg, Texas, 미국, 78539
- 모병
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, 미국, 75234
- 모병
- Altimmune Clinical Study Site
-
Forney, Texas, 미국, 75126
- 모병
- Altimmune Clinical Study Site
-
Fort Worth, Texas, 미국, 76104
- 모병
- Altimmune Clinical Study Site
-
Georgetown, Texas, 미국, 78626
- 모병
- Altimmune Clinical Study Site
-
Houston, Texas, 미국, 77004
- 모병
- Altimmune Clinical Study Site
-
Houston, Texas, 미국, 77079
- 모병
- Altimmune Clinical Study Site
-
Kingwood, Texas, 미국, 77339
- 모병
- Altimmune Clinical Study Site
-
Pasadena, Texas, 미국, 77505
- 모병
- Altimmune Clinical Study Site
-
San Antonio, Texas, 미국, 78215
- 모병
- Altimmune Clinical Study Site
-
San Antonio, Texas, 미국, 78209
- 모병
- Altimmune Clinical Study Site
-
San Antonio, Texas, 미국, 78229
- 모병
- Altimmune Clinical Study Site
-
Sugar Land, Texas, 미국, 77479
- 모병
- Altimmune Clinical Study Site
-
Waco, Texas, 미국, 76710
- 모병
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, 미국, 84405
- 모병
- Altimmune Clinical Study Site
-
West Jordan, Utah, 미국, 84088
- 모병
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, 미국, 98105
- 모병
- Altimmune Clinical Study Site
-
-
-
-
Puerto Rico
-
San Juan, Puerto Rico, 푸에르토 리코, 00927
- 모병
- Altimmune Clinical Study Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Placebo SC Injection |
|
실험적: Pemvidutide 2.4 mg
|
Pemvidutide SC Injection |
|
실험적: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical Outcome Event
기간: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
기간: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
기간: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
기간: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
기간: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
기간: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
공동 작업자 및 조사자
스폰서
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- ALT-801-301
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .